安徽安科生物工程（集团）股份有限公司 独立董事 2024 年度述职报告 各位股东及股东代表： 作为安徽安科生物工程（集团）股份有限公司（以下简称"公司"）第八届董 事会的独立董事，在 2024 年度工作中，本人严格按照《公司法》《上市公司独立 董事管理办法》等有关法律法规和《公司章程》、《独立董事专门会议工作制度》 等公司相关的规定和要求，诚实、勤勉、独立的履行职责，积极出席相关会议，认 真审议董事会各项议案，对公司重大事项发表了独立意见，充分发挥了独立董事及 专门委员会委员的作用。 作为法律专业人士，基于自身的专业经验和专业能力，为公司提供法律意见， 加强公司的风险管理，提升公司的治理水平，促进公司合规运作。对公司内控体系 的建设、予以持续关注并提出合理性建议。现就本人 2024 年度履行独立董事职责 情况汇报如下： 一、参加股东大会、董事会情况 本人出席了公司 2024 年度召开的 7 次董事会，出席会议情况如下： | 本报告期应参 | 现场出席 | 以通讯方式 | 委托出席 | 缺席次 | 是否连续两次未亲自 | | --- | --- | --- | --- | --- | --- | | 加董事会次 ...

安徽安科生物工程（集团）股份有限公司 独立董事 2024 年度述职报告 2024 年度，董事会的召集召开符合法定要求，重大事项均履行了相关的审批 程序，本人对董事会上的各项议案均投赞成票，无反对票及弃权票。 本人出席了公司 2024 年度召开的 1 次股东大会，出席会议情况如下： | 本年应参加股东大会次数 | 亲自出席次数 | 委托出席次数 | 缺席次数 | | --- | --- | --- | --- | | 1 | 1 | 0 | 0 | 本人出席了公司 2024 年度召开的 7 次董事会，出席会议情况如下： | 本报告期应参 | 现场出席 | 以通讯方式 | 委托出席 | 缺席次 | 是否连续两次未亲自 | | --- | --- | --- | --- | --- | --- | | 加董事会次数 | 次数 | 参加次数 | 次数 | 数 | 参加会议 | | 7 | 7 | 0 | 0 | 0 | 否 | 各位股东及股东代表： 作为安徽安科生物工程（集团）股份有限公司（以下简称"公司"）第八届董 事会的独立董事，在 2024 年度工作中，本人严格按照《公司法》《上市公司独立董 事管理办法》等有关 ...

Financial Performance - The company's operating revenue for 2024 was ¥2,536,042,781.68, a decrease of 11.51% compared to 2023[20]. - Net profit attributable to shareholders for 2024 was ¥706,948,363.86, down 16.56% from the previous year[20]. - The cash flow from operating activities for 2024 was ¥685,371,947.09, reflecting a decline of 28.08% year-over-year[20]. - Basic earnings per share for 2024 were ¥0.4223, a decrease of 16.57% compared to 2023[20]. - Total assets at the end of 2024 increased to ¥5,135,349,855.72, up 3.73% from the end of 2023[20]. - The company reported a weighted average return on equity of 18.21% for 2024, down from 24.91% in 2023[20]. - The total amount of non-recurring gains for 2024 was ¥59,897,330.13, compared to ¥37,905,053.08 in 2023[26]. - In 2024, the company achieved operating revenue of 253,604.28 million yuan, a year-on-year decrease of 11.51%, and a net profit attributable to shareholders of 70,694.84 million yuan, down 16.56%[47]. - The decline in revenue was primarily due to decreased sales in key business segments such as biological products and traditional Chinese medicine, alongside increased market promotion expenses to support new product launches[47]. Product Development and Innovation - The company is focused on expanding its market presence and enhancing its product portfolio through new drug research and development initiatives[5]. - The company is actively developing multiple innovative drugs, including monoclonal antibodies and ADC drugs, to enhance its product pipeline[34]. - The company has invested in cutting-edge technologies such as CAR-T cell therapy and mRNA drugs, further solidifying its position in the biopharmaceutical industry[34]. - The company is advancing the construction of a new production base, with approximately 90,000 square meters completed, and is enhancing production capacity and quality management[50]. - The company is actively pursuing clinical trials for various innovative therapies, including CAR-T cell therapies and oncolytic virus drugs, to strengthen its product pipeline[57]. - The company is preparing for the production application of Acetate of Atosiban Injection, which has completed supplementary documentation and is awaiting review[64]. - The company has established a full industry chain system in the biopharmaceutical field, focusing on gene-engineered drugs and other biopharmaceutical products, with continuous enhancement of competitive advantages in new product development and quality management[65]. - The company is committed to improving its marketing strategies and brand building, utilizing social media and AI technology to enhance product visibility and market penetration[120][121]. Market Strategy and Expansion - The company is expected to enhance its international competitiveness through strategic partnerships and overseas clinical trials[31]. - The company is expanding its market presence through strategic investments and collaborations, including a cornerstone investment in Weisheng Pharmaceuticals[34]. - The company is exploring market expansion opportunities, particularly in the traditional Chinese medicine sector, to capture a larger share of the healthcare market[39]. - The company has implemented a detailed market strategy, hosting hundreds of national and provincial academic meetings to enhance brand visibility and market penetration[52]. - The company is pursuing a multi-channel business collaboration strategy by investing in high-tech pharmaceutical companies, enhancing its core competitiveness and risk resistance[72]. Governance and Compliance - The company emphasizes governance and investor relations, aiming to improve internal control systems and ensure effective communication with investors[123]. - The company has established a comprehensive internal control system to enhance governance and operational efficiency, with revisions made to the internal audit system during the reporting period[140]. - The company received an "A" grade in the Shenzhen Stock Exchange's information disclosure assessment, reflecting its commitment to transparency and investor relations[141]. - The company maintains independence from its controlling shareholder in terms of operations, personnel, assets, and finances, ensuring autonomous business capabilities[143]. - The company has a governance structure in place for its red-chip architecture, ensuring compliance with regulations[145]. Employee Development and Remuneration - The company has a structured remuneration decision-making process, with board approval for senior management compensation based on performance and position[160]. - The company is continuously improving its employee performance evaluation and incentive mechanisms to enhance overall employee satisfaction and productivity[174]. - The company has implemented a training program that combines online and offline methods to improve employee skills and management capabilities[175]. - The company’s training focuses on new employee onboarding, skill enhancement for current employees, and specialized training for specific roles[176]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 1,933.17 million[161]. Risk Management - The company acknowledges potential risks in new drug development, industry policy changes, and group management due to business integration and expansion[5]. - The company emphasizes the importance of rational investment and risk awareness for investors regarding forward-looking statements in the report[5]. - The company has established a systematic long-term supervision mechanism for subsidiaries, enhancing management efficiency and risk prevention awareness[197]. Shareholder Engagement - The company has provided opportunities for minority shareholders to express their opinions and has ensured their legal rights are protected[179]. - The company held one shareholders' meeting during the reporting period, ensuring equal treatment of all shareholders and allowing for both online and in-person voting[137]. - The company plans to submit the nomination of Du Xianyu as a non-independent director to the 2023 annual shareholders meeting for approval[147].

2025年3月20日，维昇药业在香港联交所网站发布了《分配结果公告》，安科 生物（香港）最终获配维昇药业3,092,000股股份，持股比例占其紧随全球发售完 成后已发行股份总数的2.7%（假设超额配股权未获行使）。维昇药业最终发售价 为每股68.80港元，于2025年3月21日在香港联交所主板挂牌上市，股份代号： 2561.HK。维昇药业香港上市的详细信息可参见香港联交所信息披露网站 （www.hkexnews.hk）。根据《基石投资协议》，安科生物（香港）所持股份的禁 售期为维昇药业股份上市日起六个月。 维昇药业在香港联交所上市后可能面临股价波动风险，敬请广大投资者注意 关于公司作为基石投资者参与维昇药业香港首次公开发行的 进展公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 安徽安科生物工程（集团）股份有限公司（以下简称"公司"）于2025年2月 10日召开第八届董事会第十七次会议审议通过《关于全资子公司对外投资的议 案》，同意公司使用自有资金不超过3100万美元（包括经纪佣金及征费等相关手 续费）通过全资子公司安科生物（香港）有限公司（以下简称"安科生物 ...

安科生物（ [Table_StockNameRptType] 300009） 公司覆盖 | 投资评级：买入 [Table_Rank] | | | --- | --- | | 首次覆盖 | | | 报告日期： 2025-02-27 | | | [Table_BaseData] 收盘价（元） | 8.80 | | 近 12 个月最高/最低（元） | 11.77/7.41 | | 总股本（百万股） | 1,673 | | 流通股本（百万股） | 1,222 | | 流通股比例（%） | 73.04 | | 总市值（亿元） | 147 | | 流通市值（亿元） | 108 | [公司价格与沪深 Table_Chart] 300 走势比较 -31% -15% 1% 16% 32% 2/24 5/24 8/24 11/24 2/25 安科生物 沪深300 [Table_Author] 分析师：谭国超 执业证书号：S0010521120002 邮箱：tangc@hazq.com 分析师：陈珈蔚 执业证书号：S0010524030001 邮箱：chenjw@hazq.com 联系人：李雨涵 执业证书号：S0010123070 ...

Investment Rating - The report gives a "Buy" investment rating for the company [2][11]. Core Viewpoints - The company focuses on innovative pharmaceutical products, with a multi-field layout in the biopharmaceutical industry, aiming to become a leading innovative enterprise [5][17]. - The core products include recombinant human interferon α2b "Andafeng," recombinant human growth hormone "Ansume," and trastuzumab "Ansaiting," among others [5][17]. - The company achieved a revenue of 2.866 billion yuan in 2023, a year-on-year increase of 22.94%, and a net profit of 847 million yuan, up 20.47% year-on-year [6][25]. - The company is expected to see revenue of 2.677 billion yuan in 2024, a decrease of 6.6% year-on-year, but a recovery in subsequent years is anticipated [11][13]. Summary by Sections Company Overview - Established in 1993, the company specializes in the research, production, and sales of biopharmaceuticals, focusing on gene-engineered drugs and diagnostic reagents [17][18]. - The company has been recognized as a national innovative enterprise and has established several technology platforms [17][18]. Financial Performance - The company’s revenue has grown from 636 million yuan in 2015 to 2.866 billion yuan in 2023, with a compound annual growth rate of 20.7% [25]. - In the first three quarters of 2024, the company reported a revenue of 1.921 billion yuan, a decrease of 4.95% year-on-year [6][25]. Product Segmentation - The biopharmaceutical segment is the core business, contributing significantly to overall revenue, with a revenue of 2.1 billion yuan in 2023, accounting for 73.27% of total revenue [28][36]. - The company’s growth hormone product line is expected to see significant market potential, with the domestic growth hormone market projected to grow substantially [39][40]. Market Position - The company holds a leading market share in recombinant human growth hormone, with a 16.9% market share in the domestic market as of 2023 [42]. - The competitive landscape is intensifying, with several players vying for market share in the growth hormone sector [42].

关于控股股东、实际控制人未减持公司股份 并提前终止减持计划的公告 实际控制人、控股股东、董事兼高级管理人员宋礼华先生，控股股东、实 际控制人、董事宋礼名先生保证向本公司提供的信息内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 证券代码：300009 证券简称：安科生物 公告编号：2025-009 安徽安科生物工程（集团）股份有限公司 份未发生变化，具体持股情况如下： | 股东名称 | 持股总数 | 占公司总股本比例（%） | | --- | --- | --- | | 宋礼华 | 444,278,710 | 26.63 | | 宋礼名 | 114,889,420 | 6.89 | | 合计 | 559,168,130 | 33.52 | 二、相关情况说明 1、本次提前终止减持计划不存在违反《公司法》《证券法》《上市公司董事、 监事和高级管理人员所持本公司股份及其变动管理规则》《深圳证券交易所创业 板股票上市规则》《深圳证券交易所上市公司自律监管指引第 18 号——股东及 董事、监事、高级管理人员减持股份》等法律法规及规范性文件 ...

证券代码：300009 证券简称：安科生物 公告编号：2025-008 安徽安科生物工程（集团）股份有限公司 关于董事、高级管理人员减持股份实施完成的公告 董事、高级管理人员赵辉女士保证向本公司提供的信息内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 安徽安科生物工程（集团）股份有限公司（以下简称"公司"）董事、高级 管理人员赵辉女士计划于 2024 年 12 月 12 日至 2025 年 3 月 11 日的 3 个月内以 集中竞价方式减持本公司股份 20 万股（占本公司总股本1比例 0.01%），具体内 容详见公司 2024 年 11 月 20 日在巨潮资讯网披露的公告。近日，公司收到赵辉 女士送达的《股份减持计划实施完成告知函》，截至 2025 年 2 月 14 日，赵辉女 士本次减持计划已实施完成。具体情况公告如下： 一、股东减持情况 1、股东减持股份情况 | 股东名称 | 减持方式 | 减持期间 | 减持均价 | 减持数量 | 减持股份占公司 | | --- | --- | --- | --- | --- | --- ...

事件简评 2025 年 2 月 11 日，公司发布关于公司作为基石投资者参与维昇药 业香港首次公开发行的公告。公司于 2025 年 2 月 10 日召开第八 届董事会第十七次会议审议通过《关于全资子公司对外投资的议 案》，同意公司拟使用自有资金不超过 3100 万美元（包括经纪佣 金及征费等相关手续费）通过全资子公司安科生物（香港）有限公 司，作为基石投资者参与认购 VISEN Pharmaceuticals（中文名称 "维昇药业"）拟在香港联交所发行的首次公开发行股份，并签署 《基石投资协议》，具体持股比例将根据发行市值确定。 经营分析 双方优势互补、协同效应显著，公司核心竞争力有望进一步增强。 敬请参阅最后一页特别声明 1 附录：三张报表预测摘要 根据公司公告，维昇药业的核心产品隆培促生长素是一款每周一 次的长效生长激素替代疗法。凭借其新颖的分子设计，隆培促生长 素是唯一一款在每周给药之间能够在体内持续释放未经修饰的人 生长激素的长效生长激素。在全球 3 期阳性药物对照和平行组比 较试验中，隆培促生长素已证明较短效（每日注射）人生长激素具 有优效性，已完成的中国 3 期关键性试验持续支持隆培促生长素 与短 ...

证券代码：300009 证券简称：安科生物 公告编号：2025-006 安徽安科生物工程（集团）股份有限公司 关于第八届董事会第十七次会议决议的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 安徽安科生物工程（集团）股份有限公司（下称"公司"）第八届董事会第 十七次会议于 2025 年 2 月 10 日下午 3:00 以现场会议及通讯方式召开。会议通 知于 2025 年 2 月 5 日以直接、邮件的形式送达。应到董事 12 人，实到董事 12 人，公司全体监事、高级管理人员列席会议。会议由公司董事长宋礼华先生主持， 会议召集及召开程序符合国家有关法律法规和公司章程的规定，与会董事认真审 议并形成了以下决议： 审议通过《关于全资子公司对外投资的议案》 同意公司使用自有资金不超过 3100 万美元（包括经纪佣金及征费等相关手 续费）通过全资子公司安科生物（香港）有限公司，作为基石投资者参与认购 VISEN Pharmaceuticals（中文名称"维昇药业"）拟在香港联合交易所发行的首 次公开发行股份，并签署《基石投资协议》。本次投资基于公司战略发展规划， 旨在 ...